Pfizer has reported a net income attributable to the company of $14.09bn, or $1.98 per diluted share, for the second quarter of 2013 compared to $3.25bn, or $0.43 for the second quarter of 2012.
Revenues for the second quarter of 2013 were $12.97bn, up by 7% compared to $13.97bn for the same quarter of 2012.
The company has reported a net income attributable to the company of $16.84bn, or $2.34 per diluted share, for the first half of 2013 compared to $5.05bn, or $0.67 per diluted share, for the same period of 2012.
Revenues for the first half of 2013 were $25.38bn up by 9% compared to $27.81bn for the same quarter of 2012.
Pfizer chairman and chief executive officer Ian Read said, "I am pleased with our recent accomplishments focused on creating greater value for our shareholders, including the completion of the full disposition of Zoetis which generated over $17 billion in value as well as the announcement of our new commercial model."
